Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 90.49K 84.42K 76.68K 144K 9.8M 145K 1.01M 396K 4.98M 380K 372K 16.02M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 10.13M 9.45M 8.58M 16.16M 1.1B 16.28M 114M 44.35M 558M 42.55M 41.63M 1.79B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	100%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/05/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/10/24	Top Midday Decliners	MT
15/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/09/24	Top Midday Decliners	MT
25/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Apricus Biosciences Inc Stock Nasdaq

Stocks

US03832V1098

Biotechnology & Medical Research

Valuation: Apricus Biosciences Inc

Latest news: Apricus Biosciences Inc

Analysts' recommendations: Apricus Biosciences Inc

Press Releases: Apricus Biosciences Inc

Managers and Directors: Apricus Biosciences Inc

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.69B
ARGENX SE	+0.46%	-0.97%	+23.51%	+79.34%	58.81B
LONZA GROUP AG	+0.17%	+0.35%	+6.85%	+34.55%	48.45B
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	42.84B
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	42.79B
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	41.25B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.13B
WUXI BIOLOGICS (CAYMAN) INC.	-2.07%	+1.16%	+35.00%	+26.28%	30.28B
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	24.05B
Average	+0.25%	-0.25%	+53.35%	+123.79%	43.81B
Weighted average by Cap.	+0.69%	-0.54%	+56.27%	+130.20%

	2022	2023
Net sales	-	2.2 1.97 1.84 1.67 3.14 213.11 3.17 22.07 8.62 108.38 8.27 8.09 348.41
Net income	-73.53M -65.7M -61.3M -55.68M -105M -7.11B -106M -737M -288M -3.62B -276M -270M -11.63B	-37.88M -33.85M -31.58M -28.68M -54.02M -3.66B -54.43M -379M -148M -1.86B -142M -139M -5.99B
Net Debt	4.59M 4.1M 3.83M 3.47M 6.54M 444M 6.59M 45.97M 17.96M 226M 17.23M 16.86M 726M	11.23M 10.04M 9.36M 8.5M 16.02M 1.09B 16.14M 113M 43.96M 553M 42.17M 41.26M 1.78B

End-of-day quote Nasdaq
- ^USD	-